Health and Healthcare

Wal-Mart's (WMT) Drug Addiction Is Trouble For Rivals

blue-hills1Wal-Mart (WMT) plans a significant expansion of its programs to bring inexpensive prescription drugs to its customers which will almost certainly damage margins as its competitors.

According to The Wall Street Journal, “The discount retailer is offering businesses low-priced drugs if they sign up to buy directly from Wal-Mart’s network of in-store pharmacies, rather than contracting to buy drugs through third parties known as pharmacy-benefit managers.”

It is moving a program which has done extremely well with individuals to companies that want to save money for themselves and their workers which is an almost irresistible combination.

The plan is another in a long series of moves that Wal-Mart (WMT) can make because of its size, huge customer base, and buying leverage with suppliers. Companies including Rite Aid (RAD) and Walgreen may already have relationships with corporate customers, but those relationships will prove inadequate. Wal-Mart can afford to work on very low margins in its drug operation as it picks up market share. It is in so many other businesses that make money that suffering through a profit drought to steal business from the drug store companies which do not have diverse business bases to supplement profits in a price is not a large burden.

As for the pharmacy retailers, they don’t have the balance sheets to keep up.

Douglas A. McIntyre

ALERT: Take This Retirement Quiz Now  (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.